Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 12/20 | 0.49 |
| ▸ | NPY1R | P25929 | 7/20 | 0.49 |
| ▸ | NPY2R | P49146 | 5/20 | 0.49 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.40 |
| ▸ | FNTA | P49354 | 6/20 | 0.39 |
| ▸ | FNTB | P49356 | 6/20 | 0.39 |
| ▸ | PGGT1B | P53609 | 5/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30438004 | 1.00 | NPY4R (0.49) | NPY4RNPY1RNPY2RNPY5RACE | |
| SCHEMBL18626147 | 1.00 | NPY4R (0.49) | NPY4RNPY1RNPY2RNPY5RACE | |
| SCHEMBL29889403 | 1.00 | NPY4R (0.49) | NPY4RNPY1RNPY2RNPY5RACE | |
| SCHEMBL30390626 | 1.00 | NPY4R (0.49) | NPY4RNPY1RNPY2RNPY5RACE | |
| SCHEMBL30438407 | 1.00 | NPY4R (0.49) | NPY4RNPY1RNPY2RNPY5RACE | |
| SCHEMBL29947047 | 1.00 | NPY4R (0.49) | NPY4RNPY1RNPY2RNPY5RACE | |
| SCHEMBL30438037 | 1.00 | NPY4R (0.49) | NPY4RNPY1RNPY2RNPY5RACE | |
| SCHEMBL30390819 | 0.99 | NPY4R (0.48) | NPY4RNPY1RNPY2RNPY5RACE | |
| SCHEMBL29658167 | 0.96 | NPY4R (0.45) | NPY4RNPY1RNPY2RNPY5RACE | |
| SCHEMBL23091326 | 0.96 | NPY4R (0.44) | NPY4RNPY1RNPY2RNPY5RACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250345411-A1 | VACCINATION IN NEWBORNS AND INFANTS | CureVac SE (DE) | 2025-11-13 | — | — | US | disclosed |
| US-12390520-B2 | Vaccination in newborns and infants | Cure Vac SE (DE) | 2025-08-19 | — | — | US | disclosed |
| US-20240390478-A1 | VACCINATION IN ELDERLY PATIENTS | CureVac SE (DE) | 2024-11-28 | — | — | US | disclosed |
| US-12036277-B2 | Vaccination with mRNA-coded antigens | CureVac SE (DE) | 2024-07-16 | — | — | US | disclosed |
| US-20240197857-A1 | VACCINATION WITH mRNA-CODED ANTIGENS | CureVac SE (DE) | 2024-06-20 | — | — | US | disclosed |
| US-11975064-B2 | Vaccination with mRNA-coded antigens | CureVac SE (DE) | 2024-05-07 | — | — | US | disclosed |
| US-20230285594-A1 | COMPLEXATION OF NUCLEIC ACIDS WITH DISULFIDE-CROSSLINKED CATIONIC COMPONENTS FOR TRANSFECTION AND IMMUNOSTIMULATION | CureVac SE (DE) | 2023-09-14 | — | — | US | disclosed |
| US-20230233662-A1 | VACCINATION IN NEWBORNS AND INFANTS | CureVac SE (DE) | 2023-07-27 | — | — | US | disclosed |
| US-11690910-B2 | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen | CureVac SE (DE) | 2023-07-04 | — | — | US | disclosed |
| US-11672856-B2 | Vaccination in newborns and infants | CureVac SE (DE) | 2023-06-13 | — | — | US | disclosed |